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Abstract Although initially viewed as housekeeping enzymes,
research over the last 15 years has revealed that the protein
tyrosine phosphatases (PTPs) are critical regulators of tyrosine
phosphorylation-dependent signaling events and may represent
novel targets for therapeutic intervention in a variety of human
diseases. In this review I will describe some of the key advances
in the characterization of the structure, regulation and function
of the prototypic PTP, PTP1B, and illustrate how our under-
standing of the properties of this enzyme has revealed principles
that apply to the PTP family as a whole.
$ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The reversible phosphorylation of tyrosyl residues in pro-
teins is a key element of the signaling pathways induced by
environmental stimuli that regulate cellular responses such as
growth, proliferation, di¡erentiation, metabolism and migra-
tion. Protein tyrosine phosphorylation is controlled through
the coordinated actions of protein tyrosine kinases (PTKs)
and phosphatases (PTPs). Initially it was anticipated that
there would be a small number of PTPs that serve a house-
keeping function; however, we have now come to appreciate
that the PTPs are represented by a structurally diverse family,
which in the human genome is encoded by V100 genes, that
integrates with the PTKs to maintain normal cell function
[1,2]. Not unexpectedly, disturbance of the normal balance
between PTK and PTP function results in aberrant tyrosine
phosphorylation and has been implicated in the etiology of
several human diseases, including cancer, diabetes and in£am-
mation. The prototypic member of the PTP family is the
enzyme PTP1B. This enzyme, named from a pool of PTP
activity resolved by ion-exchange chromatography, was orig-
inally puri¢ed from human placenta as a 37 kDa catalytic
domain [3,4]. The determination of its amino acid sequence
led to the elucidation of a structural relationship with CD45
[5,6], a major transmembrane protein expressed on the surface
of hematopoietic cells, and the revelation that members of the
PTP family exist in receptor-like forms with the potential to
regulate signal transduction through ligand-controlled de-
phosphorylation of tyrosyl residues in proteins. Further stud-
ies revealed that the PTP family can be subdivided into two
broad categories, the classical, pTyr-speci¢c enzymes typi¢ed
by PTP1B and CD45, and the dual-speci¢city phosphatases,
which dephosphorylate Ser/Thr as well as Tyr residues in
proteins [2]. These latter enzymes, which largely maintain
the same catalytic mechanism as the classical PTPs but display
di¡erences in the architecture of the active site, have been
implicated in fundamentally important signaling events from
control of MAP kinases in cell proliferation to the regulation
of cyclin-dependent kinases in the cell cycle. These observa-
tions helped to shift the emphasis in research into the signal-
ing function of tyrosine phosphorylation to include both
PTKs and PTPs.
Since its discovery 15 years ago, continued investigation of
PTP1B has revealed important insights into the structure, reg-
ulation and function of this enzyme, culminating in its recog-
nition as a major target for a novel therapeutic strategy for
the treatment of diabetes and obesity. In this review I will
provide a personal perspective of some of these developments
in our understanding of PTP1B and illustrate how frequently
the properties of PTP1B reveal principles that apply to the
PTP family as a whole.
2. The PTP1B protein: distinct catalytic and regulatory
domains
Although initially puri¢ed as a catalytic domain of 37 kDa,
the isolation of cDNA-encoding PTP1B revealed a full-length
form of the protein that also contains an extension of
114 residues on the C-terminal side of the catalytic domain
[7^9]. The C-terminal 35 residues are predominantly hydro-
phobic in nature and function in targeting the enzyme to the
cytoplasmic face of membranes of the endoplasmic reticulum
(ER) [10]. This was the ¢rst example of what has become an
important concept within the PTP family, which has been
referred to as the ‘zip code’ model [11]. The targeting of
PTPs to de¢ned subcellular locations contributes to the regu-
lation of their function by restricting the spectrum of sub-
strates to which they can gain access. Interestingly, alternative
mRNA splicing generates additional structural, and therefore
functional, diversity among several PTP gene products. For
example, TC-PTP, the closest relative of PTP1B, exists in
alternatively spliced forms of either 48 kDa, which, like
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PTP1B, contains a hydrophobic C-terminus and is targeted to
the ER, or 45 kDa, which lacks the hydrophobic segment and
shuttles in and out of the nucleus under the in£uence of a
bipartite nuclear localization signal [12,13]. Two spliced var-
iants of PTP1B have also been reported, the relative levels of
which are regulated by growth factors [14] or insulin [15]. This
mRNA splicing event, which leads to retention of the last
intron in the PTP1B gene, results in only minor di¡erences
in the sequence at the extreme C-terminus of the protein, but
major di¡erences in the 3P-UTR of the mRNA, the function
of which remains to be established. It is important to realize
that subcellular targeting is not the only aspect of the regu-
lation of PTP speci¢city. As discussed below, the PTPs display
speci¢city for particular substrates as a result of features in-
trinsic to the con¢guration of the PTP active site. In fact,
some PTPs have been shown to display preferences for partic-
ular sites within a de¢ned target substrate.
The C-terminal segment of PTP1B not only controls activ-
ity indirectly by regulating subcellular location, but may also
exert a direct e¡ect on catalysis. PTP1B is sensitive to proteo-
lytic cleavage by calpain, for example following engagement
of the gpIIb-IIIa integrin on the surface of platelets, which
generates a truncated, soluble 42 kDa form of the enzyme
[16]. Generation of this truncated form of PTP1B, which lacks
V75 residues from the C-terminal segment of the protein,
including the ER-targeting motif, is associated with enhanced
PTP activity, suggesting a role for the C-terminal segment in
suppressing catalytic function. Such an inhibitory role has
been demonstrated for the C-terminal segment of the closely
related enzyme TC-PTP [17]. Whether aberrant proteolytic
cleavage and activation of PTP1B occurs under pathophysio-
logical conditions is currently under investigation. Interest-
ingly, PTP1B was one of the ¢rst PTPs shown to exist as a
phosphoprotein in vivo. Several Ser/Thr phosphorylation sites
were identi¢ed in the regulatory C-terminal segment, includ-
ing phosphorylation of Ser 378 by PKC (protein kinase C)and
two sites, Ser 352 and 386, whose phosphorylation was regu-
lated in a cell cycle-dependent manner [18]. Although changes
in activity were associated with changes in phosphorylation,
the precise mechanism by which PTP1B function may be regu-
lated by phosphorylation is unclear. Nevertheless, phosphor-
ylation of members of the PTP family by protein Ser/Thr
kinases is now recognized as an important regulatory
mechanism, with examples of both activation and inhibition
of PTP function. Interestingly, this represents a mechanism of
potential cross-talk between signaling pathways, whereby ac-
tivation of protein Ser/Thr kinases may lead to changes in
tyrosine phosphorylation through e¡ects on PTP function.
There have even been reports of phosphorylation of tyrosyl
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Fig. 1. Mechanism of action and architecture of the PTP1B active
site. A: Schematic representation of the catalytic mechanism of
PTP1B. B: Structure of the active site of PTP1B. The upper part of
panel B illustrates a ribbon representation of the complex between
PTP1B and a hexapeptide substrate, modeled on an autophosphory-
lation site of the EGF receptor [23]. The secondary structure ele-
ments of the PTP1B catalytic domain are shown in blue, with the
critical elements that comprise the catalytic site highlighted as the
signature motif (yellow), WPD loop (red), pTyr loop (orange) and
Q loop (green). The lower panel illustrates a more detailed view of
the active site. The pTyr substrate peptide is shown in green and
the other structural elements and critical residues are labeled.
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residues in PTPs, including PTP1B [19,20], although the func-
tional signi¢cance of these modi¢cations largely remains to be
established.
3. PTP1B structure and mechanism
A variety of structural studies, coupled with extensive enzy-
matic and kinetic analyses from several laboratories, have
provided important insights into the mechanism of substrate
recognition and catalysis [21]. PTP-mediated catalysis pro-
ceeds via a two-step mechanism (Fig. 1A). All members of
the PTP family are characterized by the presence of a signa-
ture motif, [I/V]HCXXGXXR[S/T], which contains the cys-
teinyl residue (Cys 215 in PTP1B) that is essential for cataly-
sis. In the ¢rst step, there is nucleophilic attack by the sulfur
atom of the thiolate side chain of the Cys on the substrate
phosphate, coupled with protonation of the tyrosyl-leaving
group of the substrate by the side chain of a conserved acidic
residue (Asp 181 in PTP1B) acting as a general acid. This
leads to formation of a cysteinyl-phosphate catalytic inter-
mediate. In the second step, mediated by Gln 262, which
coordinates a water molecule, and Asp 181, which functions
as a general base, there is hydrolysis of the catalytic inter-
mediate and release of phosphate.
The ¢rst crystal structure to be solved for a member of the
PTP family was that of the 37 kDa PTP1B catalytic domain
[22]. It was solved using sodium tungstate, an analog of phos-
phate and catalytic site-directed inhibitor of PTP1B, as the
heavy atom derivative. The structure revealed a single domain
with the polypeptide chain organized into eight K-helices and
12 L-strands with a 10-stranded mixed L-sheet that adopts a
highly twisted conformation, spanning the entire length of the
molecule [22]. The signature motif, which forms the phosphate
recognition site, is located at the base of a cleft. The sides of
the cleft are formed by three motifs (Fig. 1B). The WPD loop
contains the invariant Asp residue (Asp 181 in PTP1B), which
is involved in both steps of catalysis. The Q loop contains Gln
262, which mediates hydrolysis of the cysteinyl-phosphate cat-
alytic intermediate. The pTyr loop contains a tyrosine residue
(Tyr 46 in PTP1B), which de¢nes the depth of the cleft and
contributes to the absolute speci¢city that PTP1B displays for
phosphotyrosine-containing substrates, since the smaller phos-
phoserine and phosphothreonine residues would not reach
down to the phosphate binding site.
Further insights into substrate recognition were revealed by
the structure of a complex between a peptide, representing an
autophosphorylation site of the epidermal growth factor re-
ceptor, and a catalytically inactive mutant form of PTP1B, in
which the essential Cys from the signature motif, Cys 215, was
replaced by Ser, and which retains the ability to bind substrate
even though it could not dephosphorylate it [23]. In this case,
we observed that substrate binding was accompanied by a
large conformational change in which the WPD loop closes
around the side chain of the pTyr residue of the substrate.
This causes a Phe residue (Phe 182) to stack against the phe-
nyl side chain of the substrate pTyr residue, thus stabilizing
the closed conformation of the loop, and positions the invar-
iant Asp residue (Asp 181) to function as a general acid in the
¢rst step of catalysis. In fact, PTP1B represents an example of
the concept of ‘induced ¢t’ ^ substrate binding induces a con-
formational change that creates the catalytically competent
form of the enzyme.
The structure of a PTP1B^orthovanadate complex, which is
a mimic of the pentavalent phosphorus transition state, re-
vealed H-bonding interactions between vanadate oxygen
atoms and Gln 262 and Asp 181, focusing attention on these
residues as playing a role in hydrolysis of the cysteinyl-
phosphate catalytic intermediate [24]. We generated a Gln
262CAla mutant form of PTP1B, which allowed trapping
and visualization of the catalytic intermediate in a crystal of
the mutant protein because its hydrolysis is impaired [24]. The
structure con¢rmed the roles of Gln 262 and Asp 181 in
facilitating cysteinyl-phosphate hydrolysis. It also revealed
that the WPD loop is closed over the entrance to the active
site, thereby sequestering the phosphocysteine intermediate
with water molecules at the catalytic center and preventing
the transfer of phosphate to extraneous phosphoryl acceptors.
This explains why the second step in catalysis involves hydro-
lysis, with the PTPs being unable to phosphorylate other
phosphate acceptors. In summary, through this analysis we
succeeded in visualizing each of the reaction steps in PTP-
mediated catalysis.
4. The generation of ‘substrate trapping’ mutant PTPs
The identi¢cation of substrates of PTPs is an essential step
towards a complete understanding of the physiological func-
tion of members of this enzyme family. Although mutation of
the active site Cys to Ser or Ala allows some PTPs to form a
complex with a substrate, frequently this interaction is too
weak to permit isolation of the complex, particularly from
cell lysates. Using the structural insights described above, we
de¢ned several residues in the enzyme that were important for
substrate recognition and catalysis and characterized the func-
tion of these residues further by site-directed mutagenesis. In
so doing, we generated a form of PTP1B that maintains a
high a⁄nity for substrate but does not catalyze dephosphor-
ylation e¡ectively, i.e. we converted an extremely active en-
zyme into a ‘substrate trap’ [25]. Furthermore, the residue that
is mutated to generate the substrate-trapping mutant is the
invariant catalytic acid (Asp 181 in PTP1B) that is conserved
in all members of the PTP family. Therefore, this has a¡orded
Fig. 2. Substrate-trapping mutant PTPs. Mutation of the residue
that functions as a general acid in the ¢rst step of catalysis, Asp
181 in PTP1B, to Ala, creates a catalytically impaired (toothless)
mutant PTP, which maintains a high a⁄nity for substrate but does
not catalyze dephosphorylation e¡ectively. Following expression, the
mutant PTP binds to its physiological substrates in the cell, protect-
ing them from dephosphorylation by the endogenous wild-type
PTP. The complex can be isolated and the substrates identi¢ed.
Since the general acid is conserved in all members of the PTP fam-
ily, the strategy may be applicable to all PTPs.
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us a unique approach to identi¢cation of physiological sub-
strates of PTPs in general (Fig. 2). Following expression, the
mutant PTP binds to its physiological substrates in the cell
but, because it is unable to dephosphorylate the target e⁄-
ciently, the mutant and substrate become locked in a stable,
‘dead-end’ complex. Potential substrates can be identi¢ed by
immunoblotting lysates of cells expressing the mutant PTP
with antibodies to pTyr to reveal proteins whose phosphory-
lation state is altered as a consequence of expression of the
mutant. In addition, the complex between the mutant PTP
and the pTyr substrate can be isolated by immunoprecipita-
tion and associated proteins identi¢ed by immunoblotting or,
on a larger scale, by primary sequence determination. Several
laboratories, including my own, have now applied this strat-
egy to the characterization of the physiological substrate spec-
i¢city of several PTPs, with intriguing results. The major take
home message from this work is that members of the PTP
family display exquisite substrate speci¢city in a cellular con-
text.
Our original studies using the substrate-trapping mutant
form of PTP1B (PTP1B-D181A) indicated a role for the en-
zyme in dephosphorylation of the EGF receptor PTK [25]. In
that analysis we demonstrated by immuno£uorescence that
ectopically expressed PTP1B trapping mutant and endoge-
nous EGF receptor colocalized in punctate structures in
COS cells. More recently, an elegant study using £uorescence
resonance energy transfer in PTP1B3/3 ¢broblasts reconsti-
tuted with PTP1B substrate-trapping mutant demonstrated
that dephosphorylation of EGF and platelet-derived growth
factor (PDGF) receptors occurred at speci¢c sites in the ER,
represented by these punctate structures, and required endo-
cytosis of the PTK [26]. The localization of PTP1B to the ER
frequently led to doubts being raised regarding its importance
as a regulator of PTK signaling. Now these data indicate that
PTP1B is present in a ‘dephosphorylation compartment’ that
is encountered by down-regulated PTKs before being directed
either to the lysosome or recycled to the plasma membrane.
This suggests that PTP1B acts to terminate ligand-induced
receptor-PTK signaling, rather than controlling the basal
phosphorylation status of the receptor at the plasma mem-
brane.
5. Regulation of PTP function by reversible oxidation
A substantial body of data now emphasizes the importance
of production of reactive oxygen species (ROS) as a mecha-
nism for ¢ne-tuning tyrosine phosphorylation-dependent sig-
naling pathways through transient oxidation and inactivation
of members of the PTP family. Once again, PTP1B was a
focus of early attention in this area. Due to the unique envi-
ronment of the PTP active site, the essential Cys residue of the
signature motif displays an unusually low pKK and is present
predominantly as the thiolate anion at neutral pH. Although
this enhances its nucleophilic properties, it also renders the
PTPs susceptible to oxidation with concomitant inhibition
of activity. Pervanadate inhibits PTP1B by oxidation of the
active site Cys to sulfonic acid, the triply oxidized (^SO3H)
form [27] ; however, this, and oxidation to sul¢nic acid
(^SO2H), is an irreversible modi¢cation. In contrast, H2O2,
a ROS produced in response to a variety of physiological
stimuli, leads to oxidation of PTPs to a stable, singly oxidized
sulfenic acid (^SOH) [28^30]. Again, this inhibits activity be-
cause the Cys can no longer function as a nucleophile, but this
modi¢cation is reversible and therefore can form the basis for
a mechanism for transient inhibition of PTP activity. Interest-
ingly, PTP1B has now been shown to be oxidized reversibly
under physiological conditions, for example in response to
EGF [31] and insulin [32].
One function of ROS generated in response to a physiolog-
ical stimulus is to inactivate the critical PTP(s) that provide an
inhibitory constraint upon the signal transduction pathway
induced by that stimulus, thereby enhancing tyrosine phos-
phorylation and facilitating the signaling response (Fig. 3).
Our approach to this aspect of PTP regulation has been to
harness ligand-induced oxidation as a mechanism for ‘tagging’
and thereby identifying those PTPs that are integral to the
regulation of the signaling events induced by that ligand. In
this regard we developed a modi¢ed ‘in-gel’ PTP assay to
Fig. 3. Regulation of PTP activity by reversible oxidation. Ligand-dependent activation of a receptor PTK triggers a Rac-dependent NADPH
oxidase leading to the production of ROS. ROS oxidize the active site Cys residue of members of the PTP family, converting it from a thiolate
ion (the active form) to sulfenic acid. Oxidation results in inhibition of PTP activity, thereby promoting tyrosine phosphorylation. The sulfenic
acid form of the active site Cys residue is rapdly converted to a sulfenyl-amide, protecting it from further, irreversible oxidation. This oxidation
of the PTPs is transient and the enzymes are restored to their active state due to the action of glutathione or thioredoxin, leading to termina-
tion of the tyrosine phosphorylation-dependent signal. A variety of growth factors, hormones and cytokines induce ROS production and stimu-
late tyrosine phosphorylation. By identifying which PTPs are oxidized in response to physiological stimuli one can establish links between those
PTPs and the regulation of de¢ned signaling pathways triggered by the stimuli.
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visualize PTP oxidation in response to cell stimulation. In
contrast to the e¡ects of H2O2, which induced oxidation of
multiple PTPs, the e¡ects of physiological ligands are much
more speci¢c. This approach revealed an inhibitory role for
SHP2 in the regulation of PDGF receptor signaling [29].
More recently, we have observed that insulin induced the re-
versible oxidation of both PTP1B and TC-PTP and demon-
strated that, like PTP1B, TC-PTP is an inhibitor of signaling
through the insulin receptor (manuscript submitted).
A fundamental issue for the role of reversible oxidation as a
means of regulating PTP function is the mechanism by which
oxidation produces the sulfenic acid form of the active site
Cys, while irreversible inhibition by formation of higher-oxi-
dized species is prevented. Glutathionylation of Cys 215 in
PTP1B was demonstrated and suggested as such a mechanism
[33]. We took a structural approach to the problem and have
shown that following oxidation of PTP1B with H2O2, the
sulfenic acid intermediate is rapidly converted to a sulfenyl-
amide species [34]. A covalent bond is formed between the
sulfur atom of the active site Cys and the main chain nitrogen
of the adjacent residue, Ser 216, leading to formation of a
novel ¢ve-atom ring structure at the active site. The conse-
quences for the architecture of the active site are profound.
The PTP loop, containing the signature motif, and Tyr 46,
from the pTyr loop, £ip out of the active site to adopt solvent
exposed positions, but these e¡ects are readily reversible upon
incubation of the crystals with reducing agent. This novel
oxidation-dependent post-translational modi¢cation, which
also occurs in solution, disrupts substrate recognition by
PTP1B and renders Tyr 46 susceptible to phosphorylation.
Perhaps some of the reports in the literature of tyrosine phos-
phorylation of members of the PTP family re£ect oxidation of
the enzymes. Furthermore, the conformational change in
PTP1B that accompanies sulfenyl-amide bond formation ex-
poses the oxidized Cys to reducing agents to facilitate rever-
sion to the active form of the enzyme [34]. It will be interest-
ing to ascertain whether this represents a general mechanism
for the regulation of PTP function by reversible oxidation.
6. PTP1B and oncogenesis
Due to the existence of oncoprotein PTKs, there has long
been interest in the potential role of PTPs as tumor suppres-
sors and regulators of oncogenic transformation. Expression
of PTP1B in NIH3T3 cells was shown to suppress transfor-
mation by the PTKs Neu [35] and v-Src [36]. Interestingly, it
has now been identi¢ed as the major PTP that dephosphor-
ylates and activates c-Src in human breast cancer cell lines
[37]. PTP1B has also been implicated in the control of cell
adhesion, via e¡ects on integrin signaling [38] and through
regulation of the adhesive properties of cadherin^catenin com-
plexes [39]. Changes in the level of expression of PTP1B have
been noted in several human diseases, particularly those asso-
ciated with disruption of the normal patterns of tyrosine
phosphorylation, including certain cancers. My lab became
interested in this area when we demonstrated that the expres-
sion of PTP1B is induced speci¢cally by the p210 Bcr-Abl
oncoprotein, a PTK that is directly responsible for the initial
manifestations of chronic myelogenous leukemia [40]. These
e¡ects coincided with the ability of PTP1B to antagonize p210
Bcr-Abl-induced transformation [41]. Interestingly, expression
of TC-PTP was not induced and, despite its structural simi-
larity to PTP1B, TC-PTP did not antagonize p210 Bcr-Abl
function [40,41].
The induction of PTP1B expression by p210 Bcr-Abl occurs
at the level of transcription, which prompted us to character-
ize the PTP1B promoter. We found two elements that are
important for expression from the human PTP1B promoter.
We identi¢ed a p210 Bcr-Abl responsive sequence (PRS),
which was required for stimulation of activity in response to
the PTK [42]. The PRS is contained in a sequence that dis-
plays features of a stress response element and functions as a
binding site for three mammalian C2H2 zinc ¢nger proteins,
Egr-1, Sp1 and Sp3. Of these, both Sp1 and Sp3 function as
positive regulators, whereas Egr-1 represses Sp3-mediated
transactivation of the PTP1B gene. Furthermore, expression
of p210 Bcr-Abl results in down-regulation of the levels of
Egr-1. Our data illustrate that the reciprocal actions of Sp1/
Sp3 and Egr-1 are an important aspect of the regulation of
PTP1B expression in response to the p210 Bcr-Abl oncopro-
tein [42]. In addition to the PRS, we also characterized an
enhancer sequence and identi¢ed the transcription factor
Y-box binding protein-1 (YB-1) as a PTP1B enhancer binding
protein [43]. The nucleic acid binding domain of YB proteins
is highly conserved throughout evolution from bacteria to
humans, displaying 43% identity with the cold shock response
protein cs7.4 from Escherichia coli, suggestive of a fundamen-
tally important function. YB proteins bind single- and double-
stranded DNA and RNA and have been implicated in both
transcriptional activation and repression, functioning directly
as transcription factors and indirectly by altering promoter
conformation. Although originally identi¢ed in terms of their
ability to recognize a DNA sequence termed a Y box, the YB
proteins are now known to recognize motifs with little sim-
ilarity to the classical Y box. In fact, there is no recognizable
Y-box motif in the PTP1B enhancer and so this interaction
could not have been predicted from analysis of the promoter
sequence.
Using Rat1 ¢broblasts, we observed that overexpression of
YB-1 led to an increase in the levels of PTP1B. Furthermore,
depletion of YB-1, by expression of a speci¢c antisense con-
struct, led to anV70% decrease in expression of PTP1B, but
no change in the level of TC-PTP. Expression of antisense
YB-1 resulted in increased sensitivity to insulin and enhanced
signaling through the cytokine receptor gp130, which was sup-
pressed by re-expression of PTP1B. These data illustrate that
by targeting YB-1, the levels of PTP1B and signaling through
insulin and cytokine receptors can be manipulated [43]. Inter-
estingly, we observed a correlation between the expression of
YB-1 and that of PTP1B across a panel of cancer cell lines.
Furthermore, we demonstrated that the reported increases in
the expression of PTP1B in skeletal muscle of Goto^Kakazaki
non-obese, insulin-resistant type II diabetic rats, compared to
control non-diabetic rats, coincided with increased expression
of YB-1. These data are consistent with a functional relation-
ship between PTP1B and YB-1 in both physiological and
pathophysiological conditions and suggest that it may be pos-
sible to manipulate PTP1B activity therapeutically by control-
ling its level of expression [43].
7. PTP1B and the regulation of metabolic signaling
The above data touch on some of the most exciting recent
developments in the study of PTP1B. Early characterization
FEBS 27378 12-6-03 Cyaan Magenta Geel Zwart
N.K. Tonks/FEBS Letters 546 (2003) 140^148144
of the enzyme puri¢ed from human placenta illustrated its
ability to antagonize insulin signaling when injected into
Xenopus oocytes [44,45]. Since then a variety of studies have
explored regulatory links between PTP1B and the insulin re-
ceptor, including the use of neutralizing antibodies, over-
expression and substrate-trapping strategies. Furthermore,
there have been several reports of alterations in the levels of
expression and activity of various PTPs, including PTP1B, in
models of diabetes and obesity, as well as in clinical specimens
(reviewed in [46,47]). Although the details of these reports are
inconsistent, more recent analyses of quantitative trait loci
and mutations in the PTP1B gene in humans support the
concept that aberrant expression of PTP1B may contribute
to diabetes and obesity. For example, a mutation in the
3P-UTR of the PTP1B gene, which leads to stabilization of
its mRNA, has been associated with increased insulin resis-
tance [48]. Two additional mutations in the coding region of
PTP1B, one of which disrupts a potential regulatory phos-
phorylation site in the C-terminal segment of the protein,
are also associated with type II diabetes [49,50]. Perhaps the
most exciting data, however, have come from the development
of PTP1B knockout mice.
In a landmark paper, it was shown that ablation of the
PTP1B gene yielded mice displaying characteristics suggesting
that inhibition of PTP1B function would be an e¡ective strat-
egy for the treatment of diabetes and obesity [51]. The
PTP1B3/3 mice display enhanced sensitivity to insulin. In
the fed state the levels of serum glucose and insulin were lower
in the knockouts than the wild-type littermates and they
showed enhanced sensitivity in glucose and insulin tolerance
tests. These e¡ects coincided with enhanced tyrosine phos-
phorylation of the insulin receptor in muscle and liver.
More surprising was the observation that ablation of PTP1B
conferred resistance to obesity induced by a high-fat diet [51].
A parallel study, utilizing a di¡erent strategy to disrupt the
PTP1B gene, targeting exon 1 rather than exons 5/6 as in [51],
yielded very similar results [52]. This latter study illustrated
that the enhanced insulin sensitivity that accompanies disrup-
tion of PTP1B was tissue-speci¢c, occurring in skeletal muscle
but not adipose tissue. Furthermore, these mice, which are
characterized by a decrease in adipocyte volume, but not adi-
pocyte number, display increases in both basal metabolic rate
and total energy expenditure. Perhaps just as important as
what was observed is what was not. The mice did not show
a predisposition to cancer, despite the potential of PTP1B to
regulate growth factor receptor PTK signaling. For example,
although there is a close structural relationship between insu-
lin and IGF-1 (insulin-like growth factor 1) receptor PTKs,
and there are data to indicate enhanced phosphorylation and
activity of the IGF-1 receptor in PTP1B-de¢cient cell lines
[53], the PTP1B-de¢cient mice do not display phenotypes as-
sociated with aberrant IGF-1-induced signaling. It appears
that although ablation of PTP1B expression does lead to hy-
perphosphorylation of receptor PTKs, compensatory mecha-
nisms are induced to prevent hyperactivation of the signaling
pathways triggered by these receptors [54].
By integrating crystallographic, kinetic and peptide binding
studies, we de¢ned the molecular basis of speci¢city in the
interaction between PTP1B and activation loop of the IR
and observed that the sequence E/D-pY-pY-R/K was impor-
tant for optimal recognition of the insulin receptor by PTP1B
[55]. Of particular importance is the presence of tandem pTyr
residues; PTP1B displays 70-fold higher a⁄nity for tandem
pTyr-containing peptides derived from the insulin receptor
activation loop relative to mono-pTyr derivatives. In light of
this observation, we tested whether the presence of the motif
could be used to predict other physiological substrates of
PTP1B. Interestingly, seven PTK subtypes contain this motif
in their activation loop. We focused our analysis on the JAK
(Janus kinase) subfamily of PTKs and showed that JAK2 and
TYK2 are physiological substrates of PTP1B [56], illustrating
that PTP1B may also be an important physiological regulator
of cytokine signaling. Interestingly, the satiety hormone leptin
exerts its e¡ects through a receptor in the hypothalamus that
displays the hallmarks of a cytokine receptor. On the basis of
our observations, we predicted that PTP1B may normally
function as a negative regulator of leptin signaling in the brain
and that the resistance of PTP1B-knockout mice to high-fat
diet-induced obesity may arise from e¡ects on leptin signaling
[56]. Thus, aberrant down-regulation of members of the JAK
subfamily of PTKs may contribute to the resistance to weight
gain displayed by PTP1B-de¢cient mice. Interestingly, experi-
ments in the knockout mice have illustrated such a role for
PTP1B [57,58]. The de¢nition of consensus phosphorylation
sites has proven to be an important tool in signal transduction
research for the identi¢cation of substrates for protein ki-
nases. The observation that D/E-pY-pY-K/R is a consensus
substrate recognition site for PTP1B suggests that this concept
may also be applicable to protein phosphatases, such as
PTP1B, and that consensus recognition sites may also exist
for other PTPs.
8. The development of PTP1B as a therapeutic target
As current lifestyles lead to enhanced potential for obesity,
with its predilection to insulin resistance, our susceptibility to
diabetes and the associated cardiovascular problems that con-
stitute ‘metabolic syndrome’ represent one of the major
healthcare challenges of the 21st century. One therapeutic
strategy in this area involves the search for insulin sensitizers,
drugs that can ameliorate the insulin-resistance phenotype. A
problem with existing insulin sensitizers, such as the thiazoli-
dinedione PPAR-Q agonists, is their tendency to induce weight
gain. The phenotype of the PTP1B knockout mouse suggests
that an inhibitor of this PTP will address both obesity and
insulin resistance, thereby presenting a unique therapeutic op-
portunity. This potential was dramatically reinforced with the
demonstration that antisense oligonucleotides to PTP1B re-
duced the levels of the phosphatase in liver and fat, but not
in muscle, in ob/ob and db/db mice, resulting in enhanced
insulin sensitivity [59].
The standard approach of high-throughput screening of
libraries of small molecules to identify drug candidates
presents a number of problems unique to members of the
PTP family. The active site of PTPs, such as PTP1B, is highly
charged, as might be expected from our understanding of the
catalytic mechanism and the importance of the phosphate
group in substrate binding. Consequently, many of the inhib-
itors described to date are themselves highly charged, thus
limiting bioavailability. Furthermore, although the suscepti-
bility of the essential active site Cys residue to oxidation
underlies a mechanism for ¢ne-tuning tyrosine phosphoryla-
tion-dependent signaling, it also renders the PTPs extraordi-
narily sensitive to inhibition by oxidizing agents in assays in
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vitro [4]. Therefore, great care must be taken in characterizing
the mechanisms by which compounds inactivate these en-
zymes in high-throughput screening assays to avoid such
non-speci¢c oxidizing agents.
The quest for inhibitors of PTP1B has attracted the atten-
tion of a large number of laboratories from both academia
and industry. Already there are 40 crystal structures of com-
plexes of PTP1B with substrates or inhibitors in the Protein
Data Bank database. These illustrate both the potential and
the challenges of drug development against this target. Inter-
estingly, structural insights into the recognition of substrates
by PTP1B have revealed how speci¢city is achieved, raising
hopes that it may also be possible to design selective inhibitors
of individual PTPs. For example, PTP1B preferentially recog-
nizes the IR activation loop that is phosphorylated on both
Tyr 1162 and 1163. The pTyr 1162 residue binds to the cata-
lytic center, while the adjacent phosphotyrosyl residue, pTyr
1163, is located within a shallow groove on the surface of
PTP1B connected to the active site by a channel [55]. This
was previously identi¢ed as ‘a second aryl-phosphate binding
site’ [60], prompting much speculation about the possibility of
generating inhibitors with enhanced speci¢city and a⁄nity
that engage both this and the catalytic site simultaneously.
However, it is important to note that this ‘second site’ is
not a clearly de¢ned pocket like the active site. The interac-
tion between pTyr 1163 of the substrate and PTP1B is dom-
inated by salt bridges between the phosphate group and the
side chains of Arg 24 and Arg 254 in the enzyme, with spec-
i¢city for pTyr binding to this site being based upon the
length of the phosphorylated residue and the positioning of
these arginines [55]. Therefore, compounds that bind to this
site may also be charged, thereby exacerbating the problems
already experienced at the active site. In fact, attempts to
design compounds that bind to both sites simultaneously
have generated inhibitors with nanomolar potency, but which
are highly charged and, therefore, will have limited capacity to
cross the plasma membrane [61]. Other high-a⁄nity, bidentate
inhibitors have been generated that contain two pTyr mim-
etics; however, crystallographic analyses of their interaction
with PTP1B illustrate a mode of binding that does not involve
this second site [62^65]. Crystal structures of complexes of
PTP1B and peptide substrates, either the IR activation loop
[55] or an autophosphorylation site in the EGF receptor (Fig.
4) [23], revealed the importance of the guanidinium side chain
of Arg 47 of PTP1B in hydrogen bonding to the carboxylate
group of acidic residues on the N-terminal side of the pTyr
substrate site. The side chain of Arg 47, a residue that is
poorly conserved within the PTP family, is £exible, accommo-
dating various combinations of residues N-terminal to the
substrate pTyr site, and explaining the preference of PTP1B
for acidic residues at these positions [23,66]. In fact, these
bidentate inhibitors have been shown to interact with
PTP1B in a similar manner to substrates, with Arg 47 playing
an important role in binding the second pTyr-mimetic
[62,64,65]. Interestingly, an early strategy for the design of
PTP1B antagonists was to begin with peptides containing
pTyr analogs, for example based on substrates, and modify
them to reduce their peptidic character, creating small mole-
cule inhibitors [67^69].
In an alternative approach, the compound 2-(oxalylamino)-
benzoic acid was identi¢ed as a general, reversible and com-
petitive inhibitor of members of the PTP family [70]. In an
elegant series of studies, this compound has been modi¢ed to
create speci¢city toward inhibition of PTP1B. In one ap-
proach, its interaction with Asp 48, a residue that is important
in H-bonding interactions with main-chain N atoms in the
peptide substrate [23], was manipulated. A basic nitrogen
was introduced into the compound, not only to facilitate in-
teraction between the inhibitor and Asp 48 in PTP1B, but also
to induce repulsion between the inhibitor and other PTPs that
contain an Asn residue in the equivalent position [71]. Addi-
tional possibilities have been explored, including exploiting
the presence of a Gly residue at position 259 in PTP1B, which
permits access to the second pTyr binding site adjacent to the
catalytic center, in contrast to nearly all other PTPs, which
have a large hydrophobic residue at the cognate position that
blocks access to the site [55,72]. By derivatizing 2-(oxalylami-
no)-benzoic acid with a bulky group, in such a way as to
engage the channel created by the presence of Gly 259, bind-
ing to PTP1B is promoted. Speci¢city is further enhanced by
steric hindrance between the compound and the large hydro-
phobic residues that block the channel in the majority of the
PTPs, which excludes the modi¢ed inhibitors [73]. These ex-
amples provide a dramatic illustration of the potential to gen-
erate speci¢city in PTP-inhibitor interactions.
9. Conclusions and perspectives
Although we have witnessed substantial progress in charac-
terizing the structure, regulation and function of PTP1B, and
in exploring strategies to inhibit that function, a drug that
targets PTP1B is still a long way o¡. A compound termed
PTP-112, which demonstrated e⁄cacy as an anti-hyperglyce-
mic agent in ob/ob mice, was withdrawn from Phase II trials
due to unsatisfactory clinical e⁄cacy and dose-limiting side
e¡ects. Similar compounds to PTP-112 activated PPAR-Q,
raising the possibility of targets other than PTP1B in the
cell [74]. Clearly, the development of the ¢rst PTP1B-based
therapeutic will require further study.
In light of the structural similarities between the catalytic
Fig. 4. Interaction of PTP1B with a synthetic peptide substrate. The
¢gure illustrates a surface representation of PTP1B and its interac-
tion with a hexapeptide substrate, DADEpYL, modeled on a site of
autophosphorylation in the EGF receptor PTK, as described in [23].
The pTyr residue of the substrate is buried in the active site. Resi-
dues on the surface of PTP1B that have been implicated in interac-
tions with substrates and inhibitors are highlighted.
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domains of the various PTPs, and perhaps in£uenced by the
global changes in tyrosine phosphorylation induced by the
PTP inhibitor vanadate, it has been suggested that it may
not be possible to generate active site-directed PTP inhibitors
of su⁄cient speci¢city for therapeutic development. Interest-
ingly, similar criticisms were leveled at the protein kinases;
however, not only have we witnessed the development of pro-
tein kinase inhibitors as drugs, but also they are targeted to
the ATP binding site, a feature shared by all of the kinases
[75]. There are many opportunities to explore further the pos-
sibilities for building speci¢city into PTP inhibitors. As illus-
trated already in examples in the literature, there are com-
pounds that induce closure of the catalytic site WPD loop,
whereas others engage the enzyme in such a way as to main-
tain the open, inactive conformation of the WPD loop, with
its greater binding surface. Progress to date has already high-
lighted the potential in further exploration of the region sur-
rounding Arg 47 and Asp 48, as well as Gly 259 and access to
the second pTyr binding site, in generating inhibitor speci¢city
toward PTP1B [71,73]. All studies to date have focused on
truncated PTP1B constructs comprising the catalytic domain.
It will be interesting also to pursue the role of the regulatory
C-terminal segment of PTP1B, to test whether it interacts with
the active site. As this segment is less conserved than the
catalytic domain, it may o¡er additional opportunities to ex-
ploit speci¢city in inhibitor design. The problem represented
by the tendency for the most potent inhibitors also to be
highly charged will have to be addressed. Novel pTyr mim-
etics [76], as well as prodrug strategies involving modi¢cation
of the charged groups with neutral hydrolyzable moieties such
as esters, are currently under investigation. Ultimately, it may
not be possible to generate small molecule inhibitors with the
appropriate combination of a⁄nity, speci¢city and bioavail-
ability, in which case powerful new technologies, such as
RNA interference, may o¡er alternative strategies for inhibi-
tion of PTP function in a therapeutic context.
Various approaches, from the development of substrate-
trapping mutants to gene ablation, have highlighted the po-
tential for PTPs to display exquisite substrate speci¢city in
vivo and to function as regulators of fundamentally important
signal transduction events. Therefore, it is important to re-
member that there is more to the PTP family than just
PTP1B! With the completion of the human genome sequence
it has been possible to de¢ne the number of PTP genes as
V100 (see the website http://ptp.cshl.edu, and the parallel
site http://science.novonordisk.com/ptp, for a detailed analysis
of the PTP family). The diversity of the ‘PTP-ome’ is further
enhanced through such mechanisms as alternative splicing,
alternative promoter usage and various post-translational
modi¢cations. Additional links between PTPs and human dis-
eases, including cancer, in£ammation and infectious disease,
have already been established and it is likely that more will be
de¢ned. Hopefully, further characterization will establish new
functions for these enzymes and perhaps portray the PTPs as
a platform for the development of novel therapeutics in a
variety of disease states.
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